Pulmonary hypertension (PH) is a serious and progressive lung disease, defined by an elevation of pulmonary artery pressure, and frequently complicated by right ventricular failure and premature death. Optimal management, including medical therapy, depends upon an accurate diagnosis, a dedicated team consisting of knowledgeable physicians and allied healthcare providers, and a familiarity with the available PAH-specific medications, their benefits, and side effects. Based on Canadian and international expert consensus, it is strongly recommended that PAH patients should be managed at PH centres with demonstrated expertise. As such, Health Canada mandates that PAH-targeted medications can only be prescribed from dedicated centres of excellence.
The McMaster University PH Program at St. Joseph’s Health Healthcare is a Nationally Recognized site of PH excellence. We review approximately 125 consultations annually and manage a prevalent population of 150 patients with Group 1 PAH and CTEPH. Given our location within the Firestone Institute for Respiratory Health, the emphasis is also applied to the evaluation and management of Group 3 PH and sarcoid-related PH. Focus is applied to both clinical excellence and the application of the clinical experience to innovative research projects utilizing both local and national registry data.
Yearly on November 30. Off-cycle training is accepted, please inquire about off-cycle training with the Fellowship Director.
Funding for the PH fellowship will be flexible depending on the specific nature and training objectives of the fellowship candidate. Options include:
Training will be delivered in the ambulatory setting with inpatient consultations as required. The main objective of the training is to provide clinical training in several overlapping areas of respiratory medicine. Points of emphasis will include:
Evaluation of Fellow performance and educational initiative will be centred on: